entity

MGEA5 (OGA)

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MGEA5 (OGA): its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5Connections
1Hypotheses
1Analyses
4Outgoing
1Incoming
0Experiments

Wiki Pages (9)

Knowledge base pages for this entity

O-GlcNAcase (OGA) Inhibitor Landscape — Programs, Mechanisms, Companies

therapeutic · 3763 words

oga-inhibition-tau

mechanism · 2692 words

Yin-Yang Hypothesis (O-GlcNAcylation vs. Phosphorylation Competition)

mechanism · 2530 words

AL-207 — Alectos Therapeutics OGA Inhibitor

therapeutic · 2328 words

MGEA5 — O-GlcNAcase (OGA)

gene · 1779 words

Outgoing (4)

TargetRelationTypeStr
neurodegenerationassociated_withdisease0.40
neurodegenerationimplicated_indisease0.40
o_glcnacase___glycosylation_signalinginvolved_inpathway0.40
OGAco_associated_withgene0.30

Incoming (1)

SourceRelationTypeStr
h-46e028b6targetshypothesis0.50

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Selective OGA Inhibition as 'Tau Stabilization' Strategy Wit 0.433 neurodegeneration Which tau PTMs are both disease-specific

Mentioning Analyses (1)

Scientific analyses that reference this entity

Which tau PTMs are both disease-specific and druggable with selective small mole

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.459

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found